New drug aims to control stubborn hepatitis b virus
NCT ID NCT06550128
Summary
This study is testing an investigational drug called AHB-137 in people with a specific type of chronic hepatitis B who are already taking standard antiviral pills. The main goal is to see if adding AHB-137 can further reduce the amount of virus in the blood and potentially allow some patients to safely stop their long-term medication. Researchers will measure virus levels, safety, and how patients feel throughout the treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS B, CHRONIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Friendship Hospital, Capital Medical University
Beijing, China
-
Mengchao Hepatobiliary Hospital of Fujian Medical University
Fuzhou, Fujian, China
-
Nanfang Hospital, Southern Medical University
Guangzhou, China
-
The First Hospital of Jilin University
Jilin, China
-
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, China
-
The third People's Hospital of Zhenjiang
Zhenjiang, Jiangsu, China
Conditions
Explore the condition pages connected to this study.